Show simple item record

dc.contributor.authorCiriza Astrain, Jesús
dc.contributor.authorSáenz del Burgo Martínez, Laura ORCID
dc.contributor.authorGurruchaga Iribar, Haritz ORCID
dc.contributor.authorBorras, Francesc E.
dc.contributor.authorFranquesa, Marcella
dc.contributor.authorOrive Arroyo, Gorka
dc.contributor.authorHernández Martín, Rosa María ORCID
dc.contributor.authorPedraz Muñoz, José Luis ORCID
dc.date.accessioned2018-11-28T13:04:47Z
dc.date.available2018-11-28T13:04:47Z
dc.date.issued2018-05-21
dc.identifier.citationDrug Delivery 25(1) : 1147-1160 (2018)es_ES
dc.identifier.issn1071-7544
dc.identifier.issn1521-0464
dc.identifier.urihttp://hdl.handle.net/10810/29932
dc.description.abstractThe combination of protein-coated graphene oxide (GO) and microencapsulation technology has moved a step forward in the challenge of improving long-term alginate encapsulated cell survival and sustainable therapeutic protein release, bringing closer its translation from bench to the clinic. Although this new approach in cell microencapsulation represents a great promise for long-term drug delivery, previous studies have been performed only with encapsulated murine C2C12 myoblasts genetically engineered to secrete murine erythropoietin (C2C12-EPO) within 160 mu m diameter hybrid alginate protein-coated GO microcapsules implanted into syngeneic mice. Here, we show that encapsulated C2C12-EPO myoblasts survive longer and release more therapeutic protein by doubling the micron diameter of hybrid alginate-protein-coated GO microcapsules to 380 mu m range. Encapsulated mesenchymal stem cells (MSC) genetically modified to secrete erythropoietin (D1-MSCs-EPO) within 380 mu m-diameter hybrid alginate-protein-coated GO microcapsules confirmed this improvement in survival and sustained protein release in vitro. This improved behavior is reflected in the hematocrit increase of allogeneic mice implanted with both encapsulated cell types within 380 mu m diameter hybrid alginate-protein-coated GO microcapsules, showing lower immune response with encapsulated MSCs. These results provide a new relevant step for the future clinical application of protein-coated GO on cell microencapsulation.es_ES
dc.description.sponsorshipAuthors thank the support to research on cell microencapsulation from the University of the Basque Country UPV/EHU (EHUa 16/06 to L.SB) and the Basque Country Government (Grupos Consolidados, No ref: IT907-16 to JL.P).es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectgraphene oxidees_ES
dc.subjectcell microencapsulationes_ES
dc.subjectstem cellses_ES
dc.subjecterythropoietines_ES
dc.subjectimmune responsees_ES
dc.subjectmesenchymal stem-cellses_ES
dc.subjectl-lysine microcapsuleses_ES
dc.subjectstromal cellses_ES
dc.subjectnonhuman-primateses_ES
dc.subjectc2c12 myoblastses_ES
dc.subjectdrug-deliveryes_ES
dc.subjectmechanismses_ES
dc.subjectmicroencapsulationes_ES
dc.titleGraphene oxide enhances alginate encapsulated cells viability and functionality while not affecting the foreign body responsees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly citedes_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.tandfonline.com/doi/full/10.1080/10717544.2018.1474966es_ES
dc.identifier.doi10.1080/10717544.2018.1474966
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited
Except where otherwise noted, this item's license is described as 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited